Moderately elevated LDL cholesterol/dyslipidaemia/cardiovascular risk markers in perimenopausal women Nutritional, Metabolic, Endocrine
Conditions
Interventions
Participants are randomly allocated to an intervention group or a control group after baseline assessment. Participants in the intervention group consume 250 mL of 0.5% fermented buttermilk daily for
Sponsors
Latvia University of Life Sciences and Technologies
Eligibility
Sex/Gender
Female
Age
45 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 45-55 years 2 .Perimenopausal status 3. Moderately elevated low-density lipoprotein cholesterol within the previous 6 months, defined as LDL-C 3.01-4.12 mmol/L 4. Stable body weight during the previous 6 months, defined as change within +/- 2 kg
Exclusion criteria
Exclusion criteria: 1. Consumption of buttermilk 5-7 times per week 2. History of primary hyperlipidaemia 3. History of cardiovascular disease, including ischaemic heart disease, myocardial infarction, stroke, chronic heart failure, angina or arrhythmia 4. Endocrine diseases, including type 1 or type 2 diabetes, thyroid disorders, adrenal disease or secondary renal failure; 5. Liver disease, including non-alcoholic fatty liver disease, alcoholic fatty liver disease, hepatitis, cirrhosis or chronic liver failure 6. Chronic kidney disease or nephrotic syndrome 7. History of gastrointestinal surgery 8. Hormonal therapy 9) Immunosuppressive therapy; 10) Pharmacological treatment for hyperlipidaemia or hypertension, including medicines or dietary supplements; 11) Lactose intolerance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in low-density lipoprotein cholesterol concentration (LDL-C) measured using venous blood samples using standard clinical laboratory blood analysis in an accredited laboratory. The result is reported in mmol/L at baseline and after 28 days of intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in total cholesterol concentration measured using Total cholesterol concentration measured in venous blood samples using standard clinical laboratory blood analysis in an accredited laboratory. The result is reported in mmol/L at baseline and after 28 days of intervention.;Change in high-density lipoprotein cholesterol concentration (HDL-C) measured using venous blood samples using standard clinical laboratory blood analysis in an accredited laboratory. The result is reported in mmol/L at baseline and after 28 days of intervention;Change in triglyceride concentration measured using venous blood samples using standard clinical laboratory blood analysis in an accredited laboratory. The result is reported in mmol/L at baseline and after 28 days of intervention | — |
Countries
Latvia
Contacts
Public ContactSvetlana Aleksejeva
Outcome results
None listed